EMA Withdrawn: Osigraft (eptotermin alfa) — Olympus Biotech International Limited

View source ↗

Summary

The EMA withdrew Osigraft (eptotermin alfa) from the market for tibial fracture indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tibial Fractures

Drugs mentioned

• Osigraft (eptotermin alfa)

Snippet

Status: Withdrawn. Therapeutic area: Tibial Fractures. MAH: Olympus Biotech International Limited. Decision date: 22/08/2014